A Phase II Trial of Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site.
Latest Information Update: 25 Nov 2014
At a glance
- Drugs Bevacizumab (Primary) ; Erlotinib (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- 22 Jan 2009 Actual end date (Jan 2009) added as reported by ClinicalTrials.gov.
- 22 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Nov 2005 New trial record.